Skip to content
PeptideFactSheets
In clinical trialsEarly human evidence

Plain-English fact sheet

Kisspeptin

Also known as kisspeptin-54, kisspeptin-10, metastin

Fertility and reproductive healthSexual healthCognition and brain

Kisspeptin is a natural regulator of the reproductive hormone pathway with early human research in IVF and neuroendocrinology, but no FDA-approved drug product.

Quick answer

Kisspeptin can activate reproductive-hormone signaling in people and has been studied as an egg-maturation trigger in IVF research. It is not FDA approved for fertility, libido, testosterone, mood, or other consumer uses.

By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.

What is Kisspeptin?

Kisspeptins are related peptides made from the KISS1 protein. They stimulate gonadotropin-releasing hormone neurons and sit near the top of the reproductive hormone cascade.

Kisspeptin-54 and kisspeptin-10 differ in length and exposure; findings from one formulation or setting should not be silently applied to another.

Why are people interested in it?

Human studies have examined hormone release, puberty biology, IVF egg maturation, sexual and emotional brain processing, and reproductive disorders.

The pathway is compelling, but changing a hormone signal is not the same as proving better fertility, sexual function, mood, or long-term health.

Current regulatory status

In clinical trials

Kisspeptin has no FDA-approved drug product. Human research includes completed Phase 2 IVF studies, while FDA has described limited safety information and potential peptide-quality concerns for compounded kisspeptin-10.

What is it approved for?

No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.

What is it being studied for?

Egg maturation during IVF
Reproductive hormone release
Hypothalamic amenorrhea and other reproductive disorders
Sexual and emotional brain processing

Investigational areas

  • Triggering egg maturation in selected IVF settings
  • Diagnosing or treating reproductive hormone disorders
  • Neuroendocrine and behavioral research

Evidence snapshot

Early human evidence

Controlled human studies confirm reproductive-hormone effects and show that kisspeptin-54 can trigger egg maturation in selected IVF research populations. Larger comparative trials and long-term outcomes remain limited.

Potential benefits being researched

  • A completed Phase 2 program showed that kisspeptin-54 could produce mature eggs in selected people undergoing IVF.
  • Human crossover studies demonstrate short-term effects on luteinizing hormone and some brain-response measures, not proven fertility or mental-health benefits.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Short-term research has not established a complete safety profile for repeated or broader use.
  • FDA identifies potential immune reactions, peptide impurities, and limited route-specific safety information for compounded kisspeptin-10.
  • Changing reproductive-hormone signaling may create different risks across sex, age, pregnancy status, and endocrine conditions.

What we still do not know

  • Whether it improves live-birth outcomes compared with established IVF approaches
  • Long-term reproductive and metabolic safety
  • Which formulation and patient groups, if any, offer a favorable benefit-risk balance
  • Whether brain-imaging or hormone changes translate into meaningful daily-life outcomes

Plain-English takeaway

Kisspeptin is one of the more credible experimental reproductive peptides because human physiology and IVF studies exist. It remains investigational, and hormone changes are not a shortcut to proven fertility or sexual benefits.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    ClinicalTrials.gov: kisspeptin in IVF

    Completed Phase 2 study with posted results on egg maturation during IVF.

  2. 2
    Kisspeptin-54 egg-maturation study

    Original human study of kisspeptin-54 as an egg-maturation trigger.

  3. 3
    Randomized study of sexual and emotional brain processing

    Controlled human mechanistic study that does not establish a therapeutic benefit.

  4. 4
    FDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.